713 related articles for article (PubMed ID: 29896193)
41. [Clinical guidelines for the use of dimethyl fumarate in relapsing-remitting multiple sclerosis].
Alifirova VM; Boiko AN; Vlasov YV; Davydovskaya MV; Zakharova MN; Malkova NA; Popova EV; Sivertseva SA; Spirin NN; Khachanova NV; Shmidt ТЕ
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(1):97-102. PubMed ID: 28252608
[TBL] [Abstract][Full Text] [Related]
42. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
[TBL] [Abstract][Full Text] [Related]
43. Aberrant expansion of follicular helper T cell subsets in patients with systemic lupus erythematosus.
Jin X; Chen J; Wu J; Lu Y; Li B; Fu W; Wang W; Cui D
Front Immunol; 2022; 13():928359. PubMed ID: 36119056
[TBL] [Abstract][Full Text] [Related]
44. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
Giovannoni G; Gold R; Fox RJ; Kappos L; Kita M; Yang M; Sarda SP; Zhang R; Viglietta V; Havrdova E
Clin Ther; 2015 Nov; 37(11):2543-51. PubMed ID: 26526385
[TBL] [Abstract][Full Text] [Related]
45. Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study.
Kresa-Reahl K; Repovic P; Robertson D; Okwuokenye M; Meltzer L; Mendoza JP
Clin Ther; 2018 Dec; 40(12):2077-2087. PubMed ID: 30470580
[TBL] [Abstract][Full Text] [Related]
46. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
Ochi H; Niino M; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820
[TBL] [Abstract][Full Text] [Related]
47. Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate.
Carrieri PB; Carbone F; Perna F; Bruzzese D; La Rocca C; Galgani M; Montella S; Petracca M; Florio C; Maniscalco GT; Spitaleri DL; Iuliano G; Tedeschi G; Della Corte M; Bonavita S; Matarese G
Metabolism; 2015 Sep; 64(9):1112-21. PubMed ID: 25986733
[TBL] [Abstract][Full Text] [Related]
48. Fulminant rebound of relapsing-remitting multiple sclerosis after discontinuation of dimethyl fumarate: A case report.
Harmel P; Schlunk F; Harms L
Mult Scler; 2018 Jul; 24(8):1131-1133. PubMed ID: 29708444
[TBL] [Abstract][Full Text] [Related]
49. Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study.
Ernst FR; Barr P; Elmor R; Wong SL
Curr Med Res Opin; 2017 Dec; 33(12):2099-2106. PubMed ID: 28906152
[TBL] [Abstract][Full Text] [Related]
50. Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.
Naismith RT; Wundes A; Ziemssen T; Jasinska E; Freedman MS; Lembo AJ; Selmaj K; Bidollari I; Chen H; Hanna J; Leigh-Pemberton R; Lopez-Bresnahan M; Lyons J; Miller C; Rezendes D; Wolinsky JS;
CNS Drugs; 2020 Feb; 34(2):185-196. PubMed ID: 31953790
[TBL] [Abstract][Full Text] [Related]
51. Circulating T helper and T regulatory subsets in untreated early rheumatoid arthritis and healthy control subjects.
Pandya JM; Lundell AC; Hallström M; Andersson K; Nordström I; Rudin A
J Leukoc Biol; 2016 Oct; 100(4):823-833. PubMed ID: 27190305
[TBL] [Abstract][Full Text] [Related]
52. A pilot study on the characteristics of circulating T follicular helper cells in liver transplant recipients.
Zhang K; Sun YL; Yang F; Shi YC; Jin L; Liu ZW; Wang FS; Shi M
Transpl Immunol; 2018 Apr; 47():32-36. PubMed ID: 29360498
[TBL] [Abstract][Full Text] [Related]
53. Cross-sectional analysis of peripheral blood mononuclear cells in lymphopenic and non-lymphopenic relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate.
Lee CH; Jiang B; Nakhaei-Nejad M; Barilla D; Blevins G; Giuliani F
Mult Scler Relat Disord; 2021 Jul; 52():103003. PubMed ID: 34118574
[TBL] [Abstract][Full Text] [Related]
54. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA
Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
[TBL] [Abstract][Full Text] [Related]
55. Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity.
Longbrake EE; Mao-Draayer Y; Cascione M; Zielinski T; Bame E; Brassat D; Chen C; Kapadia S; Mendoza JP; Miller C; Parks B; Xing D; Robertson D
Mult Scler; 2021 May; 27(6):883-894. PubMed ID: 32716690
[TBL] [Abstract][Full Text] [Related]
56. Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity.
Liebmann M; Korn L; Janoschka C; Albrecht S; Lauks S; Herrmann AM; Schulte-Mecklenbeck A; Schwab N; Schneider-Hohendorf T; Eveslage M; Wildemann B; Luessi F; Schmidt S; Diebold M; Bittner S; Gross CC; Kovac S; Zipp F; Derfuss T; Kuhlmann T; König S; Meuth SG; Wiendl H; Klotz L
Brain; 2021 Nov; 144(10):3126-3141. PubMed ID: 34849598
[TBL] [Abstract][Full Text] [Related]
57. Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies.
Montes Diaz G; Hupperts R; Fraussen J; Somers V
Autoimmun Rev; 2018 Dec; 17(12):1240-1250. PubMed ID: 30316988
[TBL] [Abstract][Full Text] [Related]
58. Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS.
Talbot J; Højsgaard Chow H; Holm Hansen R; von Essen MR; Sellebjerg F
J Neuroimmunol; 2021 Dec; 361():577756. PubMed ID: 34739914
[TBL] [Abstract][Full Text] [Related]
59. Real-Word Effectiveness and Safety of Dimethyl Fumarate in a Multiple Sclerosis Portuguese Population.
Barros A; Sequeira J; de Sousa A; Parra J; Brum M; Pedrosa R; Capela C
Clin Neuropharmacol; 2020; 43(3):55-60. PubMed ID: 32384308
[TBL] [Abstract][Full Text] [Related]
60. Effects of anti-CD20 therapy on circulating and intrathecal follicular helper T cell subsets in multiple sclerosis.
El Mahdaoui S; Hansen MM; Hansen MB; Hvalkof VH; Søndergaard HB; Mahler MR; Romme Christensen J; Sellebjerg F; von Essen MR
Clin Immunol; 2024 Jul; 264():110262. PubMed ID: 38788886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
